Is the combinational administration of doxorubicin and glutathione a reasonable proposal?

Acta Pharmacologica Sinica
Bo-Yu ShenYan Liang

Abstract

The combinational administration of antioxidants and chemotherapeutic agents during conventional cancer treatment is among one of the most controversial areas in oncology. Although the data on the combinational usage of doxorubicin (DOX) and glutathione (GSH) agents have been explored for over 20 years, the duration, administration route, and authentic rationality have not yet been fully understood yet. In the current study, we systematically investigated the pharmacokinetics (PK) and pharmacodynamics (PD) with both in vivo and in vitro models to elucidate the influence of GSH on the toxicity and efficacy of DOX. We first studied the cardioprotective and hepatoprotective effects of GSH in Balb/c mice, H9c2, and HL7702 cells. We showed that coadministration of exogenous GSH (5, 50, and 500 mg/kg per day, intragastric) significantly attenuated DOX-induced cardiotoxicity and hepatotoxicity by increasing intracellular GSH levels, whereas the elevated GSH concentrations did not affect the exposure of DOX in mouse heart and liver. From PK and PD perspectives, then the influences of GSH on the chemotherapeutic efficacy of DOX were investigated in xenografted nude mice and cancer cell models, including MCF-7, HepG2, and Caco-2 cells, w...Continue Reading

References

Mar 22, 2001·British Journal of Haematology·T Bachleitner-HofmannH Gisslinger
Oct 23, 2001·International Journal of Cancer. Journal International Du Cancer·T AsakuraT Shibasaki
Jan 28, 2004·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Satu MännistöDavid J Hunter
Oct 21, 2004·The Cochrane Database of Systematic Reviews·G BjelakovicC Gluud
Oct 30, 2004·The Journal of Nutrition·Kenneth A Conklin
Nov 4, 2004·Integrative Cancer Therapies·Kenneth A Conklin
Sep 17, 2005·CA: a Cancer Journal for Clinicians·Gabriella M D'Andrea
Jul 27, 2007·Cardiovascular Toxicology·Hernán Cortés-Funes, Cyntia Coronado
Apr 7, 2010·Explore : the Journal of Science and Healing·Elena Ladas, Kara M Kelly
Sep 26, 2013·European Journal of Cell Biology·Gabriela Nestal de MoraesRaquel C Maia
Jul 10, 2014·The New England Journal of Medicine·Navdeep S Chandel, David A Tuveson
Dec 15, 2015·Science·Colleen R Reczek, Navdeep S Chandel

❮ Previous
Next ❯

Citations

Aug 27, 2019·Frontiers in Oncology·Sai LiKang Peng

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISA
flow cytometry

Software Mentioned

Prism

Related Concepts

Related Feeds

Cardiotoxicity

Cardiotoxicity refers to the muscle damage or dysfunction of heart electrophysiology caused by drug intake or due to disease complications. It is a well-known side effect of several cytotoxic drugs, especially of the anthracyclines and can lead to long term morbidity. Here is the latest research.